Silicon Laboratories Inc. — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended October 1, 2011 (third quarter of fiscal 2011), not 2010 Q3 as stated in the request metadata. The financial statements are unaudited; amounts below are in millions except per-share data.
Business context and reporting period
Silicon Laboratories designs analog-intensive, mixed-signal integrated circuits and operates as a fabless semiconductor company, relying on third parties for wafer fabrication, assembly and testing. Products serve communications, consumer, industrial, automotive, medical and power-management markets. The company acquired timing-solutions provider Spectra Linear in January 2011.
Financial performance
| Metric | Q3 FY2011 | Q3 FY2010 | Nine months FY2011 | Nine months FY2010 |
|---|---|---|---|---|
| Revenue | $119.1 | $120.2 | $364.9 | $381.5 |
| Gross profit / margin | $72.9 / 61.2% | $78.7 / 65.5% | $221.3 / 60.6% | $253.2 / 66.4% |
| Operating income | $13.9 | $19.3 | $34.9 | $75.7 |
| Net income | $11.3 | $18.2 | $22.7 | $60.4 |
| Diluted EPS | $0.26 | $0.40 | $0.50 | $1.28 |
| Operating cash flow | Not stated for quarter | Not stated for quarter | $65.6 | $83.5 |
Revenue declined 0.9% year over year for the quarter and 4.3% for the nine-month period. Q3 unit volumes rose 4.6% while average selling prices fell 4.4%; for the nine months, unit volumes fell 7.0% and average selling prices rose 3.6%. Management attributed lower gross margin primarily to product mix; the nine-month decline also reflected lower sales, Spectra Linear-related charges and a one-time charge for canceled in-process material. Operating expenses were $59.0 million for Q3 and $186.4 million year to date; R&D increased year over year, while SG&A was lower.
Financial position, liquidity and capital allocation
- At October 1, cash and cash equivalents were $108.2 million, short-term investments $174.9 million, and long-term investments $17.8 million. Management cited $283.1 million in cash, cash equivalents and short-term investments as principal liquidity.
- Current assets were $426.8 million versus current liabilities of $86.7 million. Total assets were $677.3 million; total liabilities $106.0 million; stockholders’ equity $571.3 million.
- The balance sheet reports $19.3 million of long-term obligations and other liabilities; the filing does not provide a clear separate total for conventional debt. The company paid $7.2 million on debt assumed with Spectra Linear during the nine-month period.
- Cash and cash equivalents decreased $30.4 million from the start of the fiscal year. Investing activities provided $16.9 million; financing activities used $112.8 million, including $110.1 million of share repurchases.
- The prior $150 million repurchase program was completed in August 2011. In October 2011, the board authorized a new program of up to $50 million through April 2012. The October authorization occurred after the quarter-end.
- Accounts receivable increased to $58.4 million from $45.0 million; DSO rose to 44 days from 36. Inventory declined to $38.4 million from $39.5 million; DOI fell to 75 days from 87.
Changes, outlook and notable items
- Year-to-date net income fell to $22.7 million from $60.4 million. The effective tax rate rose to 38.0% from 20.7%, mainly reflecting Spectra Linear-related tax charges and nondeductible costs, and a lower foreign tax benefit. Q3 tax rate was 20.9%, compared with 6.4% a year earlier, when nonrecurring tax benefits lowered the prior-year rate.
- Management expected Q4 FY2011 revenue to range from 3% above to 3% below Q3 sequentially, with diluted EPS of $0.21–$0.27. It expected R&D expense to increase in absolute dollars and SG&A to remain relatively stable. Fiscal 2011 capital expenditures were projected at approximately $10–$15 million.
- Management said existing cash and investment balances should meet capital requirements for at least 12 months. However, $19.3 million par value of auction-rate securities remained subject to failed auctions, with contractual maturities from 2029 to 2046; access to principal is uncertain. The company reported no other-than-temporary impairment and said it did not expect to need these funds before maturity.
- A remaining interest-rate swap was a $2.5 million liability. Its agreement requires at least $150 million of unencumbered cash and highly rated short-term investments or collateral may be required; none had been posted. The company expected to reclassify $1.8 million of swap losses into earnings over the next 12 months, offset by lower rent payments.
- Risk factors include customer and distributor concentration (Samsung exceeded 10% of nine-month revenue; three distributors represented 24%, 13% and 11%), dependence on third-party manufacturing and testing, demand and pricing volatility, product and customer concentration, and significant international exposure (87% of nine-month revenue from outside the U.S.).
- The 2001 securities class action settlement remains subject to an appeal concerning the appellant’s standing. Insurers are to fund the settlement on behalf of issuer defendants; the company says an adverse outcome if the settlement does not survive appeal could exceed insurance coverage. Other ordinary-course legal matters were not expected to have a material adverse effect. The filing also discloses contingent first-dollar lease loss exposure tied to potential headquarters property sale proceeds.
- Management reported disclosure controls were effective as of October 1, 2011, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the filing period: the document covers Q3 FY2011, despite the request’s 2010 Q3 label.
- Track whether Q4 revenue and EPS guidance was achieved, and whether weaker margins, demand and pricing trends continued.
- Assess the liquidity and valuation implications of failed-auction securities, including the company’s Level 3 valuation assumptions and restricted access to principal.
- Monitor customer and distributor concentration, receivables/DSO, and exposure to outsourced manufacturing and testing in the Pacific Rim.
- Review the new repurchase authorization, cash usage, lease-related contingent exposures, and the outstanding securities-litigation appeal.